EWA
GLUE icon

EverSource Wealth Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

EverSource Wealth Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.3K Sell
3,153
-473
-13% -$8.94K ﹤0.01% 1530
2026
Q1 		$59.6K Buy
3,626
+345
+11% +$6.6K ﹤0.01% 1764
2025
Q4 		$51.4K Buy
3,281
+294
+10% +$3.96K ﹤0.01% 1730
2025
Q3 		$22.1K Sell
2,987
-287
-9% -$1.52K ﹤0.01% 2290
2025
Q2 		$14.8K Buy
3,274
+3,074
+1,537% +$13.7K ﹤0.01% 2534
2025
Q1 		$928 Buy
200
+196
+4,900% +$1.2K ﹤0.01% 3257
2024
Q4 		$28 Buy
+4
New +$30 ﹤0.01% 3688

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EverSource Wealth Advisors's GLUE Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 13% in Q2 2026, selling an estimated $8.94K and leaving 3,153 shares worth $76.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1530.

EverSource Wealth Advisors first reported a position in GLUE in Q4 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • EverSource Wealth Advisors held 3,153 shares of Monte Rosa Therapeutics worth $76.3K as of Q2 2026.
  • EverSource Wealth Advisors sold 473 Monte Rosa Therapeutics shares in Q2 2026, an estimated $8.94K.
  • Monte Rosa Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1530 holding.
  • EverSource Wealth Advisors first reported a position in Monte Rosa Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.